Progyny, Inc.
HealthcareNASDAQ:PGNY · NASDAQ Global Select
+$0.98 today
Vol 1.27M · Avg 1.49M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.3%
avg -2.3%
ROIC
9.7%
avg -1.6%
ROA
7.9%
avg 3.1%
Analysis
ROE is currently the strongest return metric at 11.3% versus its period average of -2.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter Anevski | Chief Executive Officer & Director | $1.62M | — | 59 | $811,472.00 | 1.04% |
Melissa Cummings | Chief Operating Officer | $1.35M | — | 56 | $73,371.00 | 0.09% |
Mark S. Livingston | Chief Financial Officer | $880,386.00 | — | 60 | $77,205.00 | 0.10% |
Geoffrey Clapp | Chief Product Officer | $661,810.00 | — | 52 | $60,647.00 | 0.08% |
Allison Swartz | Executive Vice President, General Counsel & Secretary | $645,175.00 | — | 36 | $82,977.00 | 0.11% |
David J. Schlanger | Executive Chairman | $468,168.00 | — | 67 | $238,462.00 | 0.30% |
Cassandra Pratt | Chief Human Resources Officer | — | — | — | — | — |
Janet Choi | Member of the Medical Advisory Board & Chief Medical Officer | — | — | — | — | — |
Katie Higgins | Chief Commercial Officer | — | — | — | — | — |
James Hart | Vice President of Investor Relations | — | — | — | — | — |
Risa Fisher | Chief Marketing Officer | — | — | — | — | — |
Steven Leist | Chief Technology Officer | — | — | — | — | — |
Julie Stadlbauer | Chief Business Development Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.93M
Sells
20
$1.65M
Net Sentiment
+$281,147.52
Net buying
Most Active
Swartz Allison
11 transactions
1–10 of 21
Analysis
Insiders reported 1 buys worth $1.93M and 20 sells worth $1.65M over the last 12 months. That adds up to net buying of $281,147.52. Swartz Allison was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +333.5% | +11.4% (9yr)1 analysts |
| Revenue | N/A | N/A | +68.1% | +14.4% (9yr)1 analysts |
| Net Income | N/A | N/A | +363.4% | +10.1% (9yr)1 analysts |
| EBIT | N/A | N/A | N/A | +19.7% (9yr)1 analysts |
Analysis
Recent growth has been strongest in Net Income at +363.4% over three years. Forward estimates point to EBIT at +19.7% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
10x Genomics, Inc.
NASDAQ:TXG
$3.66B
Select Medical Holdings Corporation
NYSE:SEM
$2.07B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Alvotech
NASDAQ:ALVO
$1.30B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Omada Health
NASDAQ:OMDA
$1.02B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages PGNY?
Progyny, Inc. (PGNY) lists 13 active executives. The top listed executive is Melissa Cummings, Chief Operating Officer.
Are PGNY insiders buying or selling?
Recent insider activity shows net buying of $28.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.